



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/495, C07D 239/72	A1	(11) International Publication Number: WO 92/00073 (43) International Publication Date: 9 January 1992 (09.01.92)
(21) International Application Number: PCT/US91/04562 (22) International Filing Date: 26 June 1991 (26.06.91) (30) Priority data: 546,349 29 June 1990 (29.06.90) US (60) Parent Application or Grant (63) Related by Continuation US 546,349 (CIP) Filed on 29 June 1990 (29.06.90) (71) Applicant (for all designated States except US): ABBOTT LABORATORIES [US/US]; CHAD-0377/AP6D-2, One Abbott Park Road, Abbott Park, IL 60064-3500 (US).		(72) Inventors; and (75) Inventors/Applicants (for US only) : KYNCL, John, J. [US/ US]; 964 Lake Road, Lake Forest, IL 60045 (US). HOR- ROM, Bruce, W. [US/US]; 2117 North Bonnie Brook Lane, Waukegan, IL 60087 (US). (74) Agents: JANSSEN, Jerry, F. et al.; Abbott Laboratories, CHAD-0377, AP6D2, One Abbott Park Road, Abbott Park, IL 60064-3500 (US). (81) Designated States: AT (European patent), AU, BE (Euro- pean patent), CH (European patent), DE (European pa- tent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (Euro- pean patent), IT (European patent), JP, KR, LU (Euro- pean patent), NL (European patent), SE (European pa- tent), US. Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: R(+)-TERAZOSIN (57) Abstract R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine hydrochloride or a pharma- ceutically acceptable salt or hydrate thereof, substantially free of the S(-)-enantiomer.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

-1-

***R(+)*-Terazosin**Cross-Reference to Related Applications

5 This application is a continuation-in-part of co-pending application Serial No. 546,349 filed 29 June 1990.

Technical Field

10 This invention relates to compounds having pharmacological activity, to pharmaceutical compositions containing such compounds and to medical methods of treatment. More particularly, this invention concerns *R(+)*-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine, substantially free of the *S(-)*-enantiomer, its pharmaceutically acceptable salts and hydrates, to pharmaceutical compositions containing the compound, and to medical methods of
15 treatment employing the compound.

Background of the Invention

The adrenergic nervous control of bodily functions is mediated by two hormones: norepinephrine, which is generated in the adrenergic nerves and released from their endings, and
20 epinephrine, which is synthesized in the adrenal medulla and secreted into circulating blood. Both of these hormones act by binding to special receptors, designated as "adrenergic" receptors, which mediate the signal of the hormones to the intracellular biochemical mechanisms leading to stimulation of diverse physiological functions. Such functions include contraction of vascular smooth muscle (which can increase blood pressure), acceleration of heart rate, induction of
25 metabolic changes in the liver, modulation of central nervous system activity, and many others.

The adrenergic receptors are proteins embedded in cellular membranes having unique, specific amino acid sequences. Four general families of adrenergic receptors have been identified and designated α_1 , α_2 , β_1 and β_2 , all of which can be stimulated by norepinephrine and
30 epinephrine. These receptor families, however, differ such that specific agents have been developed which can selectively stimulate or inhibit each type of receptor. The degree and type of receptor selectivity for a particular agonist or antagonist agent is an important pharmacological property of such an agent and can have substantial impact on its biological activity, side effects and safety. In general, excessive stimulation of the α_1 adrenoreceptor is a hallmark of numerous
35 pathological situations and disease states such as hypertension, congestive heart failure, cardiac hyperplasia, benign prostatic hyperplasia, hyperinsulinemia, lipid disorders, impotency, as well as many others.

-2-

Importantly, the α_2 adrenoreceptors, which are very similar to the α_1 species, regulate the release of the two adrenergic hormones, norepinephrine and epinephrine, and impact on the overall level of adrenergic activity. The stimulation of α_2 receptors by an agonist inhibits the secretion of norepinephrine and epinephrine, whereas α_2 antagonist activity increases the secretion of these hormones substantially. Thus, the α_1/α_2 adrenoreceptor selectivity of an α -antagonist is very important and a desirable feature.

A number of non-selective α -adrenergic blockers, such as phenoxybenzamine and phentolamine, have prominent effects on both α_1 and α_2 receptors. It is the α_2 component of their adrenergic receptor activity which increases the adrenergic hormone secretion and thus limits their therapeutic use. Typical of such α_2 antagonist effects are increases in plasma catecholamine levels, increases in heart rate and contractility, and other highly undesirable therapeutic phenomena.

It is therefore desirable to obtain α_1 blocking agents which have greater α_1/α_2 selectivity than agents currently available. Such selectivity permits treatment of diseases characterized by elevated α_1 adrenergic activity without stimulating α_2 adrenoreceptor-mediated secretion of norepinephrine and epinephrine.

2-[4-[(Tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine, also commonly known by its generic name, terazosin, has been known for several years as an antihypertensive drug. United States Patent 4,026,894 discloses and claims the compound and United States Patent 4,112,097 discloses and claims pharmaceutical compositions containing the compound and a method of treating hypertension in mammals. United States Patent 4,251,532 discloses and claims the dihydrate of the hydrochloride salt of terazosin. The latter patent also discloses and claims pharmaceutical compositions comprising the hydrochloride dihydrate and a method of treating hypertension. While the terazosin molecule possesses a single chiral center, and can thus exist in two enantiomeric forms, none of these patents discusses this optical property of the molecule or mentions the two enantiomers.

In 1987, Nagatomo and coworkers reported the binding of the racemic compound and the individual enantiomers to α -receptors in dog brain and aorta tissue (Nagatomo, et al., Chem. Pharm. Bull., 35(4): 1629-1632 (1987)). Their data indicate that, while both enantiomers and the racemic compound bind selectively to the α_1 receptors, little difference appeared to exist between the degrees of selectivity of the two enantiomers for α_1 receptors over α_2 receptors. This article did not report any data to indicate the optical purity of the materials employed.

Summary of the Invention

It has now been found that the two enantiomeric forms of 2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine (terazosin) can be resolved, and a significant difference exists in the degree of selective binding the the R(+)- and S(-)-

enantiomers at the α -adrenergic receptors, resulting in important unexpected pharmacological properties and in their toxicity. The lack of affinity of the R(+)-enantiomer of terazosin for the α_2 receptors compared to that of either the S(-)-enantiomer or the racemic compound is believed to confer advantages on the R(+)-enantiomer as a pharmaceutical agent.

5 The present invention thus provides, in one embodiment, the compound R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine, its pharmaceutically acceptable salts and hydrates, substantially free of the S(-) enantiomer.

In another embodiment, there are provided pharmaceutical compositions comprising a therapeutically effective amount of R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-
10 dimethoxy-4-quinazolinamine, a pharmaceutically acceptable salt and/or hydrate thereof, substantially free of the S(-)-enantiomer, in combination with a pharmaceutically acceptable carrier.

In a further embodiment of the present invention there is provided a method for treating disease states characterized by abnormally elevated levels of α_1 adrenergic activity, particularly hypertension, congestive heart failure, hyperinsulinemia and benign prostatic hyperplasia, in a
15 mammal in need of such treatment comprising administering a therapeutically effective amount of R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine or a pharmaceutically acceptable salt or hydrate thereof substantially free of the S(-)-enantiomer.

Detailed Description

20 R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine or a pharmaceutically acceptable salt and/or hydrate thereof, substantially free of the S(-)-enantiomer has utility for the treatment or amelioration of disease states which are modulated by α -adrenergic receptor blocking agents. These disease states are recognized in the literature to include hypertension, congestive heart failure, cardiac arrhythmia, pulmonary
25 hypertension, arterioconstriction, and benign prostatic hyperplasia (see, for example, W. H. Frishman and Shlomo Charlap, "Adrenergic Receptors as Pharmacological Targets: The Alpha-Adrenergic Blocking Drugs," Chapter 4 in *Adrenergic Receptors in Man*, Paul A. Insel, Ed., Marcel Dekker, Inc., New York).

The term "pharmaceutically acceptable salts" refers to the relatively non-toxic, inorganic
30 and organic acid addition salts of the compound of the present invention. These salts can be prepared *in situ* during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate,
35 borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, laurylsulphonate salts and the like. (See, for

example S. M. Berge, et al., "Pharmaceutical Salts," *J. Pharm. Sci.*, 66: 1-19 (1977) which is incorporated herein by reference.) The particularly preferred salt of this invention is the hydrochloride.

In accordance with the present invention, the two enantiomers have now been substantially completely resolved, and the optical rotations of the base form of the compound have been found to be $[\alpha]_D^{22} = 34.83^\circ$ (C=1, 3N hydrochloric acid) for the R(+)-enantiomer and $[\alpha]_D^{22} = -26.9^\circ$ (C=1, 3N hydrochloric acid) for the S(-)-enantiomer. Conversion of the base forms of the two enantiomers to the hydrochloride salt dihydrate forms has produced materials having optical rotations of $[\alpha]_D^{28.5} = +23.9^\circ$ (C=1, H₂O) or greater for the dextrorotatory (i.e. R(+)) enantiomer and $[\alpha]_D^{28.5} = -23.1^\circ$ (C=1, H₂O) for the levorotatory (i.e. S(-)) enantiomer. Further purification of the R(+)-enantiomer hydrochloride dihydrate has produced material having an optical rotation of $[\alpha]_D^{24} = +25.3^\circ$ (C=1, H₂O).

The binding affinity of the substantially completely resolved enantiomers of terazosin for the α_1 and α_2 adrenoreceptors (including the α_{2A} and α_{2B} receptor subtypes) was measured using standard techniques and the results are presented below in Table 1. It is known that more than one species of α_2 adrenoreceptor can be differentiated in different tissues (D. B. Bylund, *Pharmacol. Biochem. & Behavior*, 22: 835-843 (1985). For example, human platelets have been recognized to contain an almost pure population of a sub-type of α_2 adrenoreceptor designated α_{2A} , whereas neonatal rat lung cellular membranes contain an α_2 adrenoreceptor subtype which has been designated α_{2B} . The cellular membranes of rat cerebral cortex have roughly equal numbers of α_2 adrenoreceptors of both the α_{2A} and α_{2B} subtypes.

Binding of a compound at α_1 and α_2 receptor sites is typically determined by allowing the test compound to compete with radiolabeled compounds which are known to selectively bind at each site. The technique is well known and described in the literature. The pK_I , or negative logarithm of the binding equilibrium constant, is determined from the experimental data for each receptor and the degree of selectivity of the compound in question for α_1 over α_2 receptors can be measured by the antilogarithm of the differences between the pK_I values for the two receptors.

α_1 Adrenergic binding data were obtained for the two enantiomers of terazosin and the racemic compound. Tissue from the liver and cerebral cortex of male Sprague-Dawley rats was homogenized in ice-cold assay buffer (Tris-HCl, 50 mM, pH 7.0 and 22°C). After centrifugation at 48,000 g for ten minutes the resulting pellets, containing cellular membranes containing α -receptors, were resuspended in 20 volumes of assay buffer and recentrifuged for ten minutes at 48,000 g. Liver membranes were diluted 200-fold and cerebral cortex tissues 50-fold with assay buffer.

Binding to α_1 adrenergic receptors was characterized with liver membranes in competition studies using tritiated prazosin (82 Ci/mmol, DuPont NEN; 0.2 nM) and six concentrations of each test compound at half-log incremental concentrations. Binding to α_2 adrenergic receptors was characterized in cerebral cortex tissue using tritiated rauwolscline (82.2 Ci/mMol, DuPont NEN; 0.5 nM) and six concentrations of competing test compound. Equilibrium binding was characterized after a 50 minute incubation period at 22°C. Bound radioligand was separated from radioligand in solution by filtration under vacuum through Whatman 935 AH filters. After washing five times with ice-cold assay buffer, the filters were immersed in 3 ml of Ready-Solv EP Scintillation fluid (Beckman) and counted in a Beckman LS3801 counter for 10 minutes or to a preset counting error of 4.5% at 50% counting efficiency.

To determine α_{2A} adrenoreceptor binding affinities, human platelets were harvested using the techniques described in the literature (Newman, et al., *J. Clin. Invest.*, 61: 395-402 (1978); Hoffman, et al., *Proc. Nat.. Acad. Sci.* 77: 4569-4573 (1980); and Hoffman, et al., *Endocrinology*, 110: 926-932 (1982)) These harvested platelets were used as a source of α_{2A} adrenoreceptors. Neonatal rat lung tissue was used as the source of α_{2B} adrenoreceptors and was prepared by the techniques described by Bylund, et al., *J. Pharm. Exp. Ther.*, 245: 600-607 (1988). Basically, in each instance, tissues were homogenized and a cell membrane fraction prepared and washed by centrifugation, with a final resuspension of the cell homogenate in 6.25 volumes of 25 mM glycylglycine buffer (pH 7.4) and stored in 2 ml aliquots at -80° C until used in the assay. Each assay was performed as described above, using 50 μ L of compound, water, or 10⁻⁵M phentolamine (to define non-specific binding), plus 450 μ L of tritiated rauwolscline (approximately 0.2 nM) and 500 μ L of tissue homogenate which, just prior to the assay was diluted with a further 12 volumes of gycylglycine buffer. The tube contents were mixed and allowed to equilibrate for two hours at 0° C. Radioligand bound to the receptors was separated from free radioligand using rapid filtration over Whatman GF/B filters. The retained tissue was rinsed with 45 mL washes of 50mM TRIS-HCl (pH 7.4) buffer. The filters were placed in individual scintillation vials, dried, and immersed in 3 mL of scintillation fluid. Radioactivity was determined using standard scintillation counting techniques.

The concentration at which 50% of the specifically bound radioligand was displaced by the test compound (IC₅₀) was calculated and converted to an equilibrium dissociation constant (K_I) using the formula:

$$K_I = IC_{50} / (1 + [L]/K_D)$$

where [L] is the concentration of radioligand and K_D is the equilibrium dissociation constant of the radioligand for the receptor. The mean pK_I values for the R(+), S(-), and racemic terazosin appear in Table 1.

Table 1
 α -Adrenergic Binding of *rac*-Terazosin
 and Its Enantiomers

Cmpd.	α_1 Receptor Rat Liver pK _I (\pm SEM)	α_{2A+2B} Receptor Rat Cortex pK _I (\pm SEM)	α_1/α_2 Select- ivity Ratio	α_{2A} Receptor Human platelets pK _I (\pm SEM)	α_1/α_2 Select- ivity Ratio	α_{2B} Receptor Rat Lung pK _I (\pm SEM)	α_1/α_2 Select- ivity Ratio
R(+)	9.016 ± 0.083	5.938 ± 0.178	1,197	5.668 ± 0.033	2,260	6.603 ± 0.041	260
Racemic	9.912 ± 0.101	6.569 ± 0.129	420	6.285 ± 0.052	811	8.250 ± 0.078	8.8
S(-)	9.192 ± 0.112	7.036 ± 0.199	143	6.538 ± 0.039	453	8.777 ± 0.119	2.6

*Antilog [pK_I(α_1)-pK_I(α_2)]

Examination of the data presented in Table 1 show that while R(+)-terazosin exhibited binding affinity for the α_1 adrenoreceptor similar to that of the S(-)-enantiomer and racemate, the R(+)-enantiomer was more selective for the α_1 adrenoreceptor as indicated by the α_1/α_2 selectivity ratios for the two enantiomers and the racemate. The degree of selectivity of the R(+)-enantiomer over the S(-)-enantiomer or the racemate is more pronounced when the α_1/α_2 selectivity ratios values for the α_{2A} and α_{2B} adrenoreceptor subtypes are compared.

As discussed above, compounds which are active at α_2 receptors are implicated in controlling the release of norepinephrine and related catecholamines. Thus, it is believed that R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine possesses useful pharmaceutical properties while being less subject to undesirable side effects which flow from α_2 -adrenergic binding activity.

The acute toxicities of the two enantiomeric forms of terazosin and the racemic compound were tested in adult male mice by intravenous administration, and the data appear in Table 2.

Table 2
Acute Toxicity

Compound	LD ₅₀ mg/Kg	95% Confidence Limits	Statistical Significance
R(+)	306.6	265.8 - 445.1	Rac vs R(+) = p < 0.05
Racemate	247.9	230.5 - 273.0	R(+) vs S(-) = p < 0.05
S(-)	204.6	178.8 - 234.1	Rac vs S(-) = p < 0.05

The data appearing in Table 2 show that R(+)-terazosin exhibits a roughly 50% higher LD₅₀ (i.e. lower acute toxicity) than the corresponding S(-)-enantiomer.

Racemic terazosin and the two enantiomers were tested for their effects on blood pressure and heart rate in unanesthetized spontaneously hypertensive (SH) rats, and the results are presented in Tables 3 and 4. The blood pressure of adult, male rats of the Okamoto strain to which the test compounds were administered, was measured by means of an automatically controlled pressure cuff attached to the base of the tail of each test animal. A photocell, placed distally to the cuff sensed the arterial pulse wave. Five interference-free signals, obtained during deflation of the cuff were obtained for each rat. Only those rats having a systolic blood pressure in excess of 175 mm Hg during the control were employed in the study.

Table 3
Effects of Terazosin on Blood Pressure
in Spontaneously Hypertensive Rats

Hours After Dosing	Dose (mg/Kg)	Vehicle % Change from 0-Hour Value (SEM)	Racemate % Change from 0-Hour Value (SEM)	R(+) % Change from 0-Hour Value (SEM)	S(-) % Change from 0-Hour Value (SEM)
1	0.0	-1.32 (2.8)			
	1.0		-20.52 (1.6)	-22.37 (1.7)	-25.00 (1.7)
	10.0		-36.18 (2.9)	-28.58 (2.4)	-31.81 (3.0)
5	0.0	-2.77 (2.5)			
	1.0		-8.82 (2.7)	-6.42 (1.3)	-27.25 (2.2)
	10.0		-22.60 (1.9)	-18.16 (2.4)	-30.38 (2.8)

Table 4
Effects of Terazosin on Heart Rate
in Spontaneously Hypertensive Rats

Hours After Dosing	Dose (mg/Kg)	Vehicle % Change from 0- Hour Value (SEM)	Racemate % Change from 0- Hour Value (SEM)	R(+) % Change from 0- Hour Value (SEM)	S(-) % Change from 0- Hour Value (SEM)
1	0.0	-2.93 (2.9)			
	1.0		8.81 (6.7)	-0.04 (3.5)	5.86 (3.2)
	10.0		8.58 (6.0)	-1.68 (3.5)	10.92 (5.2)
5	0.0	-9.96 (3.7)			
	1.0		-4.61 (3.8)	-6.20 (2.5)	-0.31 (4.7)
	10.0		2.44 (6.5)	-13.26 (3.3)	3.94 (5.4)

The data in Table 3 shows that R(+)-, S(-)- and racemic terazosin all produced similar lowering of blood pressure; however, the data in Table 4 show that R(+)-terazosin produced less effect on heart rate increase than either S(-)-terazosin or the racemate.

The inhibition of α_2 adrenoreceptors *in vivo* is known to facilitate the release of the neuronal transmitter, norepinephrine, which in turn can cause an increase in cardiac contractility. In a further test, racemic terazosin and the two enantiomers were tested for their effects on the levels of plasma norepinephrine in anesthetized dogs, and the results appear in Table 5. Male beagle dogs weighing between 8.2 and 13.2 Kg were anesthetized with pentobarbital. Electrocardiogram leads were attached to the dogs and a lead 11 electrocardiogram was recorded. ASwan Ganz catheter was advanced into the pulmonary artery for measurement of pulmonary artery pressure and cardiac output. Central venous pressure was measured through the proximal port of the catheter. A dual tip micromanometer (Millar Model SPC-770 7F) was advanced into the left ventricle of the heart for measurement of left ventricular pressure. The right femoral vein was cannulated for administration of the test compounds.

Following a stabilization period of sixty minutes, vehicle (0.9% NaCl) was injected at a volume of 0.1 mg/Kg. Sixty minutes later, the lower dose (0.3 mg/kg) of the test compound was administered, followed sixty minutes later by the higher dose (3.0 mg/kg). The compounds were tested in fifteen dogs each, using a randomized schedule.

Table 5
Effect of Terazosin on
Left Ventricular Contractility (dP/dt_{max})
in Anesthetized Dogs

Time (Minutes) Following Administration of An Intravenous
Dose of 3 mg/Kg

Pre-Dose	1.5	2	4	6	8	10	20	30	40	50	60
R(+)-Terazosin											
N	14	14	13	13	13	13	13	13	13	13	13
Mean	2279.64	2434.21	2432.69	2333.77	2298.23	2261.00	2249.38	2150.08	2178.08	2196.69	2221.38
SEM*	77.69	86.68	85.70	80.49	81.23	82.45	77.24	70.03	76.31	72.70	68.34
Racemic Terazosin											
N	15	15	15	15	15	15	15	15	15	14	14
Mean	2652.40	3255.53	3215.33	3087.00	3037.53	2936.67	2912.60	2873.60	2934.33	3071.73	2955.29
SEM*	172.19	257.69	233.91	221.17	229.33	192.19	195.67	209.06	227.25	276.66	250.25
S(-)-Terazosin											
N	15	14	15	15	15	15	15	15	15	13	11
Mean	2638.80	3352.64	3271.20	3119.73	3025.60	2975.20	2917.53	2834.33	2841.07	2855.80	2788.54
SEM*	152.40	253.25	222.93	170.95	167.45	173.82	166.77	159.67	155.15	143.85	107.69

*SEM = Standard error of the mean

The data in Table 5 show that there was no appreciable change in left ventricular contractility upon administration of the R(+)-enantiomer of terazosin, while administration of either the S(-)-enantiomer or the racemate produced measurable increases, even one hour after administration.

5 The present invention also provides pharmaceutical compositions which comprise one or more of the compounds of formula I above formulated together with one or more non-toxic pharmaceutically acceptable carriers. The pharmaceutical compositions may be specially formulated for oral administration in solid or liquid form, for parenteral injection, or for rectal, vaginal, or topical administration.

10 The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, or as an oral or nasal spray. The term "parenteral" administration as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

15 Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol,
20 polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

 These compositions may also contain adjuvants such as preservative, wetting agents,
25 emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such
30 as aluminum monostearate and gelatin.

 In some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may
35 depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsuled matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other

-12-

solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.

Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic.

Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq.

Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants which may be required. Ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient, compositions, and mode of administration. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the

condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required for to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

For use as an antihypertensive agent, the compound of this invention is generally dosed orally at levels of about 0.01 mg to about 250 mg, more preferably of about 0.1 mg to about 100 mg of active compound per kilogram of body weight per day to a mammalian patient. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, e.g. two to four separate doses per day.

Example 1

10 Preparation of *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine from *R*(+)-tetrahydro-2-furoic acid resolved as the brucine salt

Step 1 - Preparation of *R*(+)-tetrahydro-2-furoic acid

Using the procedure detailed in Can. J. Chem., 61:1383-1386 (1983), racemic tetrahydro-2-furoic acid was first converted to a mixture of the diastereomeric brucine salts by reaction with (-)-brucine in ethyl acetate. The crude brucine salt of *R*(+)-tetrahydro-2-furoic acid which first precipitated had a melting point of 191-197°C and an optical rotation $[\alpha]_D^{23} = -7.86^\circ$ (C=1, methanol). The material was recrystallized three times from ethyl acetate to yield material melting at 200-203°C and having an optical rotation $[\alpha]_D^{23} = -4.8^\circ$ (C=1, methanol) (literature value $[\alpha]_D = -5.8^\circ$ (C=1, methanol)).

The salt was acidified to recover *R*(+)-tetrahydro-2-furoic acid, b.p. 57-58°C at 0.1 mm Hg, refractive index, $n_D^{25} = 1.4953$, optical rotation $[\alpha]_D^{22} = +33.37^\circ$ (C=1, chloroform) (literature value $[\alpha]_D = +30.4^\circ$ (C=1, chloroform)).

25 Step 2 - Preparation of *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine

R(+)-Tetrahydro-2-furoic acid was dissolved in tetrahydrofuran and 2.0 g (0.017 mole) of dicyclohexylcarbodiimide was added followed by 3.50 g (0.017 mole) N-hydroxysuccinimide. The mixture was stirred overnight at room temperature. The precipitated dicyclohexylurea which formed was collected by filtration and the residue washed with a small amount of tetrahydrofuran. The solid was discarded and the washings added to the filtrate.

To the filtrate were added a solution of 4.91 g (0.017 mole) of 4-amino-6,7-dimethoxy-2-piperazinyl-4-quinazoline in tetrahydrofuran. The resulting mixture was stirred overnight at room temperature. The solid which had precipitated was collected by filtration and washed several times with tetrahydrofuran. The washings were combined with the filtrate which was evaporated to dryness. The residual solid was taken up in a 5/1 mixture of methylene chloride/methanol and the

resulting mixture distilled to remove the methylene chloride. The removed methylene chloride was replaced by an equal volume of methanol, at which point the product began to crystallize from solution. The solution was allowed to cool to room temperature and stand for several hours, yielding *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine, m.p. 272-274°C, optical rotation $[\alpha]_D^{22} = 34.83^\circ$ (C=1, 3N hydrochloric acid).

Example 2

Preparation of *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine, hydrochloride salt dihydrate

10 *R*(+)-Terazosin hydrochloride salt dihydrate was prepared by heating an ethanol solution of *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine to near reflux and adding slightly more than one equivalent of concentrated aqueous hydrochloric acid. Solution occurred immediately, and the mixture was allowed to cool to room temperature and stand for several hours. The precipitate which formed was collected by filtration, washed with
15 ethanol, and dried to yield *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine, hydrochloride salt dihydrate having a melting point of 260.5-263.5°C and an optical rotation $[\alpha]_D^{28.5} = +23.94^\circ$ (C=1, water).

Example 3

Preparation of *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine hydrochloride dihydrate from enzymatically resolved tetrahydro-2-furoic acid

Step 1 - Preparation of the benzyl ester of racemic tetrahydrofuroic acid

(*R,S*)-Tetrahydro-2-furoic acid (1.152 kg, 10.1 mol) was dissolved in 5 liters of
25 dichloromethane. Benzyl alcohol (1.08 kg, 10 mol) was added, followed by 10 ml of concentrated sulfuric acid. The resulting mixture was heated to reflux and maintained at that temperature, with azeotropic distillation of water derived from the reaction. When the calculated amount of water had been collected, the reaction mixture was cooled to room temperature and washed with 1 liter of 5% aqueous sodium bicarbonate solution and twice with 1 liter portions of water. The solution was
30 then dried over anhydrous magnesium sulfate, filtered, and concentrated under vacuum to yield 1.9 kg of tetrahydro-2-furoic acid benzyl ester which was found to be 92% pure by chromatographic analysis.

Step 2 - Enzymatic resolution of tetrahydro-2-furoic acid

35 Tetrahydro-2-furoic acid benzyl ester (412 g, 2.0 mol) was mixed with 5 liters of 0.1 M phosphate buffer and the pH adjusted to 7.0 with sodium hydroxide solution. Prozyme® 6

enzyme (10 g, Amano International Enzyme Co., Inc., P.O. Box 1000, Troy, VA 22974, Lot No. PR002511P) was added to the solution in one portion. The pH of the resulting mixture was maintained at pH 6.84-7.03 by means of a pH Stat adding 2M sodium hydroxide solution. The mixture was allowed to react under these conditions overnight.

5 Chloroform (500 ml) was added to quench the reaction and the mixture was stirred for an additional fifteen minutes, after which it was filtered through diatomaceous earth to remove insoluble material. The aqueous phase was extracted twice with 500 ml portions of chloroform, and the chloroform solutions were combined, dried, and evaporated. The residue was taken up in 2 liters of diethyl ether and washed twice with 500 ml portions of water, twice with 5% aqueous
10 sodium bicarbonate, and twice with water. The ether solution was then dried over anhydrous magnesium sulfate, filtered, and the solvent evaporated to yield a water-white oil.

This material was distilled under reduced pressure to yield 1.45 g of (S)-tetrahydro-2-furoic acid, b.p. 102-105°C at 0.25 mm Hg. Hydrogenolysis of this material under standard conditions followed by distillation under reduced pressure afforded 72.73 g of (S)-tetrahydro-2-furoic acid in two fractions:

15 Fraction 1: 35.93 g; b.p. 72°C at 0.25 mm Hg; $\eta_D^{25} = 1.4595$; $[\alpha]_D^{25} = -33.87^\circ$

(C = 1, CHCl₃);

Fraction 2: 36.8 g; 35.93 g; b.p. 72°C at 0.25 mm Hg; $\eta_D^{25} = 1.4595$; $[\alpha]_D^{25} = -33.07^\circ$

(C = 1, CHCl₃).

20 The original aqueous phase from the enzymatic reaction was concentrated to dryness under reduced pressure to yield a yellow/brown solid. This residue was taken up in 500 ml of water and 100 g of potassium acid phosphate were added. The resulting mixture was cooled over ice for thirty minutes after which 85% phosphoric acid was added to a pH of 2.0. The aqueous phase was extracted with three 500-ml portions of diethyl ether and the combined ether extracts were
25 dried over anhydrous magnesium sulfate and evaporated to dryness to yield a water-white oil. Reduced pressure distillation of this oil yielded 155 g of predominantly (R)-tetrahydro-2-furoic acid, contaminated with the (S)-enantiomer (b.p. 65.0°C at 0.23 mm Hg).

This material was reesterified with benzyl alcohol using the method described above. Analysis of this ester by HPLC on a chiral column indicated that the ester was about 85% the (R)-
30 enantion, and about 15% of the (S)-enantiomer. This mixture of benzyl esters was resubjected to enzymatic resolution using the method detailed above. Work-up of the product of this enzymatic process in the manner described above yielded, after vacuum distillation, 47.8 g of (R)-tetrahydro-2-furoic acid in two fractions:

Fraction 1: B.p. 73-77°C at 0.35 mm Hg; $\eta_D^{25} = 1.4595$; $[\alpha]_D^{25} = +32.85^\circ$

35 (C = 1, CHCl₃);

Fraction 2: 36.8 g; 35.93 g; b.p. 77-78°C at 0.4 mm Hg; $\eta_D^{25} = 1.4595$; $[\alpha]_D^{25} = +33.39^\circ$

(C = 1, CHCl₃).

Step 3 - Preparation of *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine, hydrochloride dihydrate

5 The title compound was prepared from the enzymatically-resolved (*R*)-tetrahydro-2-furoic acid using the methods of Step 3 of Example 1 and Example 2. $[\alpha]_D^{24} = +25.33^\circ$ (C = 1, H₂O).

Example 4

10 Preparation of *S*(-)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine

Step 1 - Preparation of *S*(-)-tetrahydrofuroic acid

Using the procedure detailed in Can. J. Chem., 61:1383-1386 (1983), racemic tetrahydro-2-furoic acid was first converted to a mixture of the diastereomeric ephedrine salts by reaction with (+)-ephedrine in ethyl acetate. The crude *S*(-)-ephedrine salt which first precipitated had a melting point of 114-115°C. The material was recrystallized four times from ethyl acetate to yield material melting at 115-117°C and having an optical rotation $[\alpha]_D^{26.5^\circ\text{C}} = +13.4^\circ$ (C=1, methanol) (literature $[\alpha]_D = +13.8^\circ$).

20 The salt was acidified to recover the *S*(-)-tetrahydro-2-furoic acid, b.p. 60°C at 0.5 mm Hg, refractive index, $n_D^{25} = 1.4582$, optical rotation $[\alpha]_D^{22} = -32.02^\circ$ (C=1, chloroform) (literature $[\alpha]_D = -30.1^\circ$ (C=1, chloroform)).

Step 2 - Preparation of *S*(-)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine

25 The procedure employed was the same as that described above in Example 1 for the *R*(+)-enantiomer, yielding *S*(-)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine, m.p. 269.5-271.1°C, optical rotation $[\alpha]_D^{22^\circ\text{C}} = -26.9^\circ$ (C=1, 3N hydrochloric acid).

Example 5

30 Preparation of *S*(-)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine, hydrochloride salt dihydrate

The procedure employed was the same as in Example 2 for the preparation of the hydrochloride salt of the *R*(+)-enantiomer. M.p. 271.5-273°C (dec.), optical rotation $[\alpha]_D^{28.5^\circ\text{C}} = -23.1^\circ$ (C=1, water).

Example 6**Determination of the Optical Purity of R(+)-Terazosin**

The material of Examples 2 and 3 was analyzed for optical purity by separation of the R(+)- and S(-)-enantiomers on a chiral AGP column (α_1 acid glycoprotein column, ChromTech, Box 512, S-145 63 Norsberg, Sweden). The mobile phase consisted of 50 mM potassium phosphate at pH 7.4 and acetonitrile in a ratio of 94/6. The flow rate was 0.9 ml/min. The mobile phase was equilibrated at 0°C-6°C. Detection of the eluate was by ultraviolet light at 254 nM. Samples of 5 μ l containing 0.1 mg/ml of compound were employed.

Example	Optical Rotation	Percent R(+)-Enantiomer
2	+ 23.94°	91
3	+ 25.33°	>99

10

While there have been described and illustrated what are believed to be the preferred embodiments of the present invention, it will be obvious to one of ordinary skill in the art that various modifications thereof can be made without departing from the scope of the invention as it is defined by the appended claims.

WE CLAIM:

1. The compound having the name *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine or a pharmaceutically acceptable salt thereof substantially free of the *S*(-)-enantiomer.
2. The compound having the name *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine having an optical rotation of at least $[\alpha]_D^{22^\circ} = 34.83^\circ$ (C=1, 3N hydrochloric acid).
3. The compound having the name *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine hydrochloride dihydrate substantially free of the *S*(-)-enantiomer.
4. The compound as defined by Claim 3 having an optical rotation of at least $[\alpha]_D^{28.5^\circ}$ (C=1, water) of $+23.9^\circ$.
5. A pharmaceutical composition comprising a therapeutically effective amount of *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine or a pharmaceutically acceptable salt thereof substantially free of the *S*(-)-enantiomer, in combination with a pharmaceutically acceptable carrier.
6. A method of treating disease states modulated by α_1 adrenergic activity in a mammal in need of such treatment while minimizing unwanted side effects resulting from α_2 adrenergic activity comprising administering a therapeutically effective amount of *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine or a pharmaceutically acceptable salt thereof substantially free of the *S*(-)-enantiomer.
7. A method of treating disease states modulated by α_1 adrenergic activity in a mammal in need of such treatment without undesirable heart rate increase resulting from α_2 adrenergic activity comprising administering a therapeutically effective amount of *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine or a pharmaceutically acceptable salt thereof substantially free of the *S*(-)-enantiomer.

8. A method of treating disease states modulated by α_1 adrenergic activity in a mammal in need of such treatment without undesirable cardiac contractility increase resulting from α_2 adrenergic activity comprising administering a therapeutically effective amount of *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine or a pharmaceutically acceptable salt thereof substantially free of the *S*(-)-enantiomer.
- 5
9. A method of treating hypertension in a mammal in need of such treatment comprising administering a therapeutically effective amount of *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine or a pharmaceutically acceptable salt thereof substantially free of the *S*(-)-enantiomer.
- 10
10. A method of treating benign prostatic hyperplasia in a mammal in need of such treatment comprising administering a therapeutically effective amount of *R*(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine or a pharmaceutically acceptable salt thereof substantially free of the *S*(-)-enantiomer.
- 15

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/04562

I. CLASSIFICATION OF SUBJECT MATTER (In several classification symbols indicate all)		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC(5): A61K 31/495, C07D 239/72		
US CL : 514/254, 544/291		
II. FIELDS SEARCHED		
Minimum Documentation Searched		
Classification System	Classification Symbols	
US CL	514/254, 544/291	
Documentation Searched other than Minimum Documentation to the extent that such Documents are Included in the Fields Searched		
III. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	"Chem. Pharm. Bull", volume 35, no. 4, 1987 T. NAGATOMO ET AL. "Andrenergic and Serotonergic receptor blocking potencies of Tetracosin, a new antihypertensive agent, as assessed by Radioligand binding Assay", pages 1629-1632. See entire document.	1,3,5-9
Y	US, A, 4,251,532 (ROTEMAN ET AL.) 17 FEBRUARY 1981 See columns 2-6.	1-10
Y	US, A, 4,026,894 (WINN ET AL.) 31 MAY 1977 See columns 1-3.	1-10
<p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
25 OCTOBER 1991	07 NOV 1991	
International Searching Authority	Signature of Authorized Officer	
ISA/US	J. VENKAT	